Journal of Inherited Metabolic Disease

, Volume 26, Issue 6, pp 513–526 | Cite as

The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: A position statement

  • T. M. Cox
  • J. M. F. G. Aerts
  • G. Andria
  • M. Beck
  • N. Belmatoug
  • B. Bembi
  • R. Chertkoff
  • S. Vom Dahl
  • D. Elstein
  • A. Erikson
  • M. Giralt
  • R. Heitner
  • C. Hollak
  • M. Hrebicek
  • S. Lewis
  • A. Mehta
  • G. M. Pastores
  • A. Rolfs
  • M. C. Sa Miranda
  • A. Zimran


N-Butyldeoxynojirimycin (NB-DNJ, miglustat 'Zavesca') is an orallyactive iminosugar which inhibits the biosynthesis of macromolecular substrates that accumulate pathologically in glycosphingolipidoses. Clinical trials of NB-DNJ in patients with Gaucher's disease demonstrate the therapeutic potential of such substrate inhibitors in the glycolipid storage disorders. However, macrophage-targetted enzyme replacement using intravenous mannose-terminated human glucocerebrosidase (imiglucerase, Cerezyme) is highly effective in ameliorating many of the manifestations of Gaucher's disease and is a treatment in widespread use. Given that imiglucerase and miglustat are now both licensed for the treatment of Gaucher's disease, there is a need to review their therapeutic status. Here the treatment of type 1 (non-neuronopathic) Gaucher disease is evaluated with particular reference to the emerging role of oral N-butyldeoxynojirimycin (miglustat) as a substrate-reducing agent. This position statement represents the consensus viewpoint of an independent international advisory council to the European Working Group on Gaucher Disease.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aerts JMFG, Hollak CEM (1997) Plasma and metabolic abnormalities in Gaucher's disease. In: Zimran A, ed. Baillikre's Clinical Haematology: Gaucher's Disease, Vol. 10. London: Bailliere-Tindall, 691–709.Google Scholar
  2. Barton NW, Brady RO, Dambrosia JM, et al (1991) Replacement therapy for inherited enzyme deficiency macrophage-targeted glucocerebrosidase for Gaucher disease. N Engl J Med 324: 1464–1470.PubMedCrossRefGoogle Scholar
  3. Beutler E, Grabowski GA (2001) Gaucher disease. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds; The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 3635–3668.Google Scholar
  4. Beutler E (1996) Effect of low dose enzyme replacement therapy on bones in Gaucher disease patients with severe skeletal involvement: commentary. Blood Cells Mol Dis 22: 113–114.CrossRefGoogle Scholar
  5. Beutler E, Gelbart T (1996) Mutation update. Glucocerebrosidase (Gaucher disease) Hum Mutat 8: 207–213.PubMedCrossRefGoogle Scholar
  6. Beutler E, Demina A, Laubscher K, et al (1995a) The clinical course of treated and untreated Gaucher disease. A study of 45 patients. Blood Cells Mol Dis 21: 86–108.PubMedCrossRefGoogle Scholar
  7. Beutler E, Kuhl W, Vaughan LM (1995b) Failure of alglucerase infused in Gaucher disease to localise in marrow macrophages. Mol Med 1: 320–324.PubMedGoogle Scholar
  8. Boot RG, Hollak CEM, Verhoek M, et al (1997) Glucocerebrosidase genotype of Gaucher disease patients in the Netherlands: limitations in prognostic value. Hum Mutat 10(5): 348-358.PubMedCrossRefGoogle Scholar
  9. Brady RO (1978) Glucosyl ceramide lipidosis: Gaucher's disease. In Stanbury JB, Wyngaarden JB, Fredickson DS, eds; The Metabolic Basis of Inherited Disease, 4th edn. New York: McGraw-Hill: 731–746.Google Scholar
  10. Brady RO, Kanfer JN, Shapiro D (1965) Metabolism of glucocerebrosides. Evidence of an enzymatic deficiency in Gaucher's disease. Biochem Biophys Res Commun 18(2): 221–225.PubMedCrossRefGoogle Scholar
  11. Conzelmann E, Sandhoff K (1983) Partial enzyme deficiency: residual activities on the development of neurological disorders. Dev Neurosci 6: 58–71.PubMedGoogle Scholar
  12. Cox TM, Schofield JP (1997) Gaucher's disease: clinical features and natural history. In: Zimran A, ed. Bailliere's Clinical Haematology: Gaucher's Disease, Vol. 10. London: Baillere-Tindall, 657–689.Google Scholar
  13. Cox T, Lachmann R, Hollak C, et al (2000) Novel oral treatment of Gaucher disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355: 1481–1485.PubMedCrossRefGoogle Scholar
  14. Damiano AM, Pastores GM, Ware JE Jr (1998) The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study. Qual Life Res 7(5): 373–386.PubMedCrossRefGoogle Scholar
  15. Elstein D, Hadas-Halpern I, Itzchaki M, et al (1996) Effect of low-dose ERT on bones in Gaucher disease patients with severe skeletal involvement. Blood Cells Mol Dis 22: 104–111.PubMedCrossRefGoogle Scholar
  16. Elstein D, Abrahamov A, Hadas-Halpern I, Zimran A (2000) Withdrawal of enzyme replace-ment therapy in Gaucher's disease. Br J Haematol 110: 488–492.PubMedCrossRefGoogle Scholar
  17. Elstein D, Dwek A, Attias D, et al (2002). A randomised study of OGT 918 as an oral therapy in patients previously treated with enzyme replacement for type 1 Gaucher disease. Presented at the Fifth Workshop of the European Working Group on Gaucher Disease, Prague, 1 4 May 2002.Google Scholar
  18. Fischl MA, Resnick L, Coombs R, et al (1994) The safety and efficacy of combination N-butyldeoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200 500 CD4 cells/mm3. J Acquired Immune Defic Syndr 7: 139–147.Google Scholar
  19. Germain DP, Kaneski CR, Brady RO (2001) Mutation analysis of the acid beta-glucosidase gene in a patient with type 3 Gaucher disease and neutralising antibody to alglucerase. Mutat Res 483(1 2): 89–94.PubMedGoogle Scholar
  20. Gielchinsky Y, Elstein D, Green R, et al (2001) High prevalence of low serum vitamin B12in a multi-ethnic Israeli population. Br J Haematol 115(3): 707–709.PubMedCrossRefGoogle Scholar
  21. Giraldo P, Pocovi M, Perez-Calvo J, Rubio-Felix D, Giralt M (2000) Report of the Spanish Gaucher's disease registry: clinical and genetic characteristics. Haematologica 85(8): 792–799.PubMedGoogle Scholar
  22. Grabowski GA, Horowitz M (1997) Gaucher's disease: molecular, genetic and enzymological aspects. In Zimran A, ed. Baillikre's Clinical Haematology: Gaucher's Disease. London: Baillere-Tindall, 635–656.Google Scholar
  23. Grabowski GA, Barton NW, Pastores G, et al (1995) Enzyme therapy in type 1 Gaucher dis-ease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 122: 33–39.PubMedGoogle Scholar
  24. Heitner R, Elstein D, Aerts J, van Weely S, Zimran A (2002) Low-dose N-butyldeoxy-nojirimycin (OGT 918) for type 1 Gaucher disease. Blood Cells Mol Dis 28(2): 127–133.PubMedCrossRefGoogle Scholar
  25. Hollak CEM, Aerts JMFG, Goudsmit R, et al (1995) Individualised low-dose alglucerase therapy for type 1 Gaucher disease. Lancet 345: 1474–1478.PubMedCrossRefGoogle Scholar
  26. Hollak CEM, Mass M, Akkerman E, den Heeten A, Aerts JMFG (2001) Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease. Blood Cells Mol Dis 27(6): 1005–1012.PubMedCrossRefGoogle Scholar
  27. Inokuchi J, Radin NS (1987) Preparation of the active isomer of 1-phenyl-2-decanoyl-amino-3-morpholino-l-propanol inhibitor of murine glucocerebroside synthetase. J Lipid Chem 28: 565–571.Google Scholar
  28. Knudson AG, Kaplan WD (1962) Genetics of the sphingolipidoses. In Aronson SM, Volk BW eds; Cerebral Sphingolipidoses. New York: Academic Press, 395.Google Scholar
  29. Lachmann RH, Platt FM (2001) Substrate reduction therapy for glycosphingolipid storage disorders. Expert Opin Invest Drugs 10(3): 455–466.CrossRefGoogle Scholar
  30. Levy-Lahad E, Zimran A (1997) Gaucher's disease: genetic counselling and population screening. In Zimran A, ed. Bailliere's Clinical Haematology: Gaucher's Disease. London: Baillere-Tindall, 779–793.Google Scholar
  31. Masek BJ, Sims KB, Bove CM, et al (1999) Quality of life assessment in adults with type 1 Gaucher disease. Qual Life Res 8: 263–268.PubMedCrossRefGoogle Scholar
  32. Maaswinkel-Mooij P, Hollak C, van Eysden-Plaisier M, et al (2000) The natural course of Gaucher disease in the Netherlands: implications for monitoring of disease manifestations. J Inherit Metab Dis 23(1): 77–82.PubMedCrossRefGoogle Scholar
  33. Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. J Am Med Assoc 282(3): 249–254.CrossRefGoogle Scholar
  34. Pastores GM, Sibille AR, Grabowski GA (1993) Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in thirty-three patients treated for 6 to 24 months. Blood 82: 408-416.PubMedGoogle Scholar
  35. Platt FM, Neises GR, Dwek RA, Butters TD (1994) N-Butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem 269: 8362–8365.PubMedGoogle Scholar
  36. Poll LW, Koch JA, Willers R, et al (2002) Correlation of bone marrow response with hematological, biochemical, and visceral responses to enzyme replacement therapy of non-neuronopathic (type 1) Gaucher disease in 30 adult patients. Blood Cells Mol Dis 28(2): 209–220.PubMedCrossRefGoogle Scholar
  37. Richards SM, Olson TA, McPherson JM (1993) Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase. Blood 82(5): 1402–1409.PubMedGoogle Scholar
  38. Rosenthal DI, Doppelt SH, Mankin HJ, et al (1995) Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics 96: 629–637.PubMedGoogle Scholar
  39. Tierney M, Pottage J, Kessler H, et al (1995) The tolerability and pharmacokinetics of N-butyldeoxynojirimycin in patients with advanced HIV disease (ACTG 100): the AIDS Clinical Trial Group (ACTG) of the National Institute of Allergy and Infectious Diseases. J Acquired Immune Defic Syndr Hum Retrovir 10: 549–553.CrossRefGoogle Scholar
  40. Vellodi A, Bembi B, de Villemeur TB, et al (2001) Management of neuronopathic Gaucher disease: a European consensus. J Inherit Metab Dis 24(3): 319–327.PubMedCrossRefGoogle Scholar
  41. vom Dahl S, Poll LW, Hdussinger D (2001) Clinical monitoring after cessation of enzyme replacement therapy in M. Gaucher. Br J Haematol 113: 1084–1186.PubMedCrossRefGoogle Scholar
  42. Weinreb NJ (2001) Interruption in enzyme replacement therapy for Gaucher disease. Br J Haematol 113: 1087–1088.PubMedCrossRefGoogle Scholar
  43. Weinreb NJ, Charrow J, Andersson HC, et al (2002) Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment; a report from the Gaucher Registry. Am J Med 113: 112–119.PubMedCrossRefGoogle Scholar
  44. Zimran A, Kay A, Gelbart T, et al (1992) Gaucher disease: clinical, laboratory, radiologic and genetic features of 53 patients. Medicine (Baltimore) 71(6): 337–353.Google Scholar
  45. Zimran A, Elstein D, Kannai R, et al (1994) Low dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype, and clinical features on response to treatment. Am J Med 97: 3–13.PubMedCrossRefGoogle Scholar
  46. Zimran A, Elstein D, Levy-Lahad E, et al (1995) Replacement therapy with imiglucerase for type 1 Gaucher's disease. Lancet 345: 1479–1480.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  • T. M. Cox
    • 1
    • 2
  • J. M. F. G. Aerts
    • 3
  • G. Andria
    • 4
  • M. Beck
    • 5
  • N. Belmatoug
    • 6
  • B. Bembi
    • 7
  • R. Chertkoff
    • 8
  • S. Vom Dahl
    • 9
  • D. Elstein
    • 10
  • A. Erikson
    • 11
  • M. Giralt
    • 12
  • R. Heitner
    • 13
  • C. Hollak
    • 14
  • M. Hrebicek
    • 15
  • S. Lewis
    • 16
  • A. Mehta
    • 17
  • G. M. Pastores
    • 18
  • A. Rolfs
    • 19
  • M. C. Sa Miranda
    • 20
  • A. Zimran
    • 21
  1. 1.Department of MedicineUniversity of Cambridge, Addenbrooke's HospitalCambridgeUK
  2. 2.Department of MedicineUniversity of CambridgeCambridgeUK
  3. 3.Department of Biochemistry, Academic Medical CentreUniversity of AmsterdamAmsterdamThe Netherlands
  4. 4.Department of PaediatricsFederico II UniversityNaplesItaly
  5. 5.Biochemisch-Genetisches LaborUniversitats-KinderklinikMainzGermany
  6. 6.Hôpital BeaujonClichyFrance
  7. 7.Istituto per l'Infanzia Burlo GarofoloTriesteItaly
  8. 8.Israeli Gaucher Patients AssociationHaifaIsrael
  9. 9.Klinik für Gastroenterologie, Hepatologie und InfektiologieUniversitätsklinikum der Heinrich-Heine-UniversitätDüsseldorfGermany
  10. 10.Gaucher ClinicShaare Zedek Medical CenterJerusalemIsrael
  11. 11.Department of PaediatricsUmea University HospitalUmeaSweden
  12. 12.Jefe del Servicio de HematologiaHospital 'Miguel Servet'ZaragozaSpain
  13. 13.Johannesburg Hospital, Department of PaediatricsUniversity of WitwatersrandSouth Africa
  14. 14.Department of Internal Medicine and HaematologyAcademic Medical CentreAmsterdamThe Netherlands
  15. 15.Institute of Inherited Metabolic DisordersPragueCzech Republic
  16. 16.Gauchers AssociationLondonUK
  17. 17.Department of HaematologyRoyal Free HospitalLondonUK
  18. 18.New York University School of MedicineNew YorkUSA
  19. 19.Klinik für Neurologie und PoliklinikUniversität RostockRostockGermany
  20. 20.Instituto de Genetica MedicaPortoPortugal
  21. 21.Gaucher Clinic, Department of MedicineShaare Zedek Medical CenterJerusalemIsrael

Personalised recommendations